In 2014, a landmark study was published demonstrating that the expression of androgen
receptor splice variant (AR-V) 7 was a negative predictive biomarker for response to …

Background In metastatic castration-resistant prostate cancer (mCRPC), androgen receptor
splice variant 7 (AR-V7) expression is associated with a low response to androgen receptor …

Background: Detection of androgen receptor (AR) splice variant-7 (AR-V7) messenger RNA
(mRNA) in circulating tumor cells (CTCs) is associated with a suboptimal response to …

The androgen receptor splice variant AR-V7 has recently been discussed as a predictive
biomarker for nonresponse to next-generation androgen deprivation therapy (ADT) in …

5001 Background: Androgen receptor splice variant-7 (AR-V7) is a truncated form of the
androgen receptor that lacks the ligand-binding domain, the target of enzalutamide and …

The PROPHECY study 1 (ClinicalTrials. gov identifier: NCT02269982) suggests that
pretreatment androgen receptor splice variant 7 (AR-V7) expression in circulating tumor …

Despite several treatment options and an initial high response rate to androgen deprivation
therapy, the majority of prostate cancers will eventually become castration-resistant in the …

Purpose We reported previously that the detection of androgen receptor splice variant-7 (AR-
V7) mRNA in circulating tumor cells (CTCs) correlated with poor outcomes from the use of …

INTRODUCTION Identification of cancer biomarkers that inform clinical decisions and
reduce the use of ineffective therapies is a major goal of precision oncology. An abnormal …

Background: androgen receptor variant 7 (AR-V7) has been suggested as potential marker
for treatment selection in men with metastatic castration-resistant prostate cancer (mCRPC) …